LivaNova PLC (LIVN)

From the record

LivaNova PLC's filings since 2017 show 2 warning events of 2 kinds: an auditor change (8-K item 4.01, the latest 2018-03-26); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2019-03-04) (its current reports).

From the record

LivaNova PLC's 10 filed years say what it did: revenue went from $965 million in fiscal 2016 to $1.4 billion in fiscal 2025, up 4.1% a year; it rose in 6 of 9 years; the deepest fall was 16% from fiscal 2018 to fiscal 2020; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, LivaNova PLC's diluted share count grew about 0.7% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 7 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, LivaNova PLC lost about 20 cents for every dollar of shareholders' money, and gross profitability: its products earned about 36 cents per dollar of everything the company owns. Leverage: it owed about 54 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

LivaNova PLC's standing among 24 graded names in its industry family: revenue of $1.4 billion in fiscal 2025 ranks in the top 10% by size; a net margin of -17.5% ranks in the top 44%; revenue growth of 10.7% a year over the last 3 filed years ranks in the top 50% (its annual reports).

From the record

LivaNova PLC's leadership, from its insiders' filings and its current reports: the chief executive on the record is Makatsaria, Vladimir (Chief Executive Officer, as filed), filing under that title since 2024-03-04, 2.7 years (top 47% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 2.7 years (bottom 26%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (top 34%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

LivaNova PLC's room to grow, from the newest filed statements (fiscal 2025): cash of $636 million against debt of $345 million leaves 11.1% of its assets as net cash, bottom 37% of its family; cash from operations less capital spending is 12.5% of revenue (top 15%); a gross margin of 67.7% (top 33%); research spending of 13.4% of revenue (bottom 48%) (its annual report).

From the record

LivaNova PLC's growth drivers, from the filed years to fiscal 2025: revenue grew 10.7% a year over the last three filed years against 4.1% over all 10, speeding up (top 7% of its family); the newest year grew 10.7% (bottom 46%); research spending grew 6% a year (top 46%); capital spending grew 45.1% a year (top 31%) (its annual reports). LivaNova PLC reported 2 lines of business in fiscal 2025: Cardiopulmonary at $785 million, Neuromodulation at $593 million. 2 of 2 grew in the latest filed year, and the largest line is 57% of revenue (its annual report).

From the record

LivaNova PLC's newest year against its own record: revenue of $1.4 billion in fiscal 2025 came in 0% below the $1.4 billion its prior three years' pace pointed to (bottom 45% of its family); net income of $242 million against a prior three-year average of $2 million (bottom 5%); a net margin of -17.5% against -0.6% before (bottom 18%) (its annual reports).